Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Pipeline Review, H2 2018
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Pipeline Review, H2 2018
SUMMARY
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) pipeline Target constitutes close to 38 molecules. Out of which approximately 33 molecules are developed by companies and remaining by the universities/institutes. The latest report Alpha Synuclein - Pipeline Review, H2 2018, outlays comprehensive information on the Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Alpha-synuclein is a protein normally found in cells all over the body. It is one of the key players in Parkinson’s. In Parkinson’s it forms clumps inside the specific nerve cells that produce the chemical dopamine. It is involved in the regulation of dopamine release and transport. It induces fibrillization of microtubule-associated protein tau. It reduces neuronal responsiveness to various apoptotic stimuli, leading to decreased caspase-3 activation.
The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 4, 5, 19 and 5 respectively. Similarly, the universities portfolio in Preclinical stages comprises 5 molecules, respectively. Report covers products from therapy areas Central Nervous System, Metabolic Disorders, Gastrointestinal, Genetic Disorders, Infectious Disease, Oncology and Ophthalmology which include indications Parkinson's Disease, Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration), Alzheimer's Disease, Lewy body Dementia, Neurodegenerative Diseases, Amyloidosis, Constipation, Down Syndrome, Familial Amyloid Neuropathies, Glaucoma, Human Immunodeficiency Virus (HIV) Infections (AIDS), Huntington Disease, Metastatic Breast Cancer, Schizophrenia, Spinal Cord Injury, Traumatic Brain Injury and Type 2 Diabetes.
Furthermore, this report also reviews key players involved in Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) pipeline Target constitutes close to 38 molecules. Out of which approximately 33 molecules are developed by companies and remaining by the universities/institutes. The latest report Alpha Synuclein - Pipeline Review, H2 2018, outlays comprehensive information on the Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Alpha-synuclein is a protein normally found in cells all over the body. It is one of the key players in Parkinson’s. In Parkinson’s it forms clumps inside the specific nerve cells that produce the chemical dopamine. It is involved in the regulation of dopamine release and transport. It induces fibrillization of microtubule-associated protein tau. It reduces neuronal responsiveness to various apoptotic stimuli, leading to decreased caspase-3 activation.
The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 4, 5, 19 and 5 respectively. Similarly, the universities portfolio in Preclinical stages comprises 5 molecules, respectively. Report covers products from therapy areas Central Nervous System, Metabolic Disorders, Gastrointestinal, Genetic Disorders, Infectious Disease, Oncology and Ophthalmology which include indications Parkinson's Disease, Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration), Alzheimer's Disease, Lewy body Dementia, Neurodegenerative Diseases, Amyloidosis, Constipation, Down Syndrome, Familial Amyloid Neuropathies, Glaucoma, Human Immunodeficiency Virus (HIV) Infections (AIDS), Huntington Disease, Metastatic Breast Cancer, Schizophrenia, Spinal Cord Injury, Traumatic Brain Injury and Type 2 Diabetes.
Furthermore, this report also reviews key players involved in Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA)
- The report reviews Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics and enlists all their major and minor projects
- The report assesses Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Overview
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Companies Involved in Therapeutics Development
AC Immune SA
AFFiRiS AG
BioArctic AB
Biogen Inc
Denali Therapeutics Inc
Fulcrum Therapeutics Inc
Genmab A/S
ICB International Inc
MedImmune LLC
Neuropore Therapies Inc
nLife Therapeutics SL
Priavoid GmbH
ProMIS Neurosciences Inc
Prothena Corp Plc
QR Pharma Inc
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Drug Profiles
ABL-301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antibodies to Inhibit Alpha-Synuclein for Glaucoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antibody to Inhibit Alpha Synuclein for Parkinson's Disease and Multiple System Atrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antibody to Inhibit Alpha-Synuclein for Neurodegenerative Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASD-004 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AV-1947D - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AV-1948D - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AV-1949D - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AV-1950D - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AV-1950R - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BAN-0805 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BIIB-054 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CLR-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DPC-003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ENT-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LuAF-82422 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MEDI-1341 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit Alpha Synuclein for Parkinson's Disease and Lewy Body Dementia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit Tau, Amyloid Beta and Alpha-Synuclein for Neurodegenerative Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit Alpha Synuclein for Central Nervous System Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NLFPD-1233 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NPT-088 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NPT-10018A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NPT-189 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NPT-20011 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PD-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PD-03 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PD-04 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Posiphen - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PRX-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
quinpramine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Alpha-Synuclein for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Alpha-Synuclein for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Alpha-Synuclein and Lcn2 for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Alpha-Synuclein for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Inhibit Alpha Synuclein for Parkinson’s Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
trehalose - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
UB-312 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Dormant Products
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Product Development Milestones
Featured News & Press Releases
Jun 26, 2018: ProMIS Neurosciences Unique Discovery Platform Generates Potential New Antibody Therapeutics for Neurodegenerative Diseases
Jun 19, 2018: Prothena Announces Phase 1b Clinical Trial Results Of PRX002/RG7935 For Parkinson's Disease Published In JAMA Neurology
Jun 18, 2018: New immunotherapy could stop progression of Parkinson’s disease
May 14, 2018: AFFiRiS Announces Encouraging Long-term Data from a Series of First-in-Human Studies Using AFFITOPE PD01A Targeting Oligomeric Alpha-synuclein in Early Parkinson's Disease Patients
Mar 28, 2018: Proclara Biosciences Presents Preclinical Data Supporting the Development of GAIM-Based Therapies for Peripheral Amyloidoses at the 16th International Symposium on Amyloidosis
Mar 26, 2018: Enterin's Phase 2a RASMET Study in Patients With Parkinson's Disease Completes Enrollment
Mar 15, 2018: AC Immune prepares for a first in human study of a promising positron emission tomography tracer for Parkinson's disease
Mar 01, 2018: AFFiRiS Announces Results of a Phase I Clinical Study Using AFFITOPEs PD01A
Mar 01, 2018: AFFiRiS Announces Results of a Phase I Clinical Study Using AFFITOPEs PD03A
Dec 04, 2017: ICBII Announces the Filing of Orphan Drug Designation Application for the Use of alpha-Synuclein-SMART Molecule in the Treatment of Multiple System Atrophy
Nov 14, 2017: Proclara Biosciences Presents New Preclinical Data on GAIM-Based Therapy NPT088 at Society for Neuroscience Annual Meeting
Nov 14, 2017: Proclara Biosciences Presents New Preclinical Data on GAIM-Based Therapy NPT189 at Society for Neuroscience Annual Meeting
Oct 13, 2017: BioArctic's Patent for its Product Candidate Antibody BAN0805, for Parkinson's Disease, is Now Granted in Europe
Jul 18, 2017: Proclara Biosciences Presents New Preclinical Data Supporting the Development of NPT189 at Alzheimer’s Association International Conference (AAIC) 2017
Jul 17, 2017: Proclara Biosciences Announces Pipeline Progress
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Overview
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Companies Involved in Therapeutics Development
AC Immune SA
AFFiRiS AG
BioArctic AB
Biogen Inc
Denali Therapeutics Inc
Fulcrum Therapeutics Inc
Genmab A/S
ICB International Inc
MedImmune LLC
Neuropore Therapies Inc
nLife Therapeutics SL
Priavoid GmbH
ProMIS Neurosciences Inc
Prothena Corp Plc
QR Pharma Inc
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Drug Profiles
ABL-301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antibodies to Inhibit Alpha-Synuclein for Glaucoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antibody to Inhibit Alpha Synuclein for Parkinson's Disease and Multiple System Atrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antibody to Inhibit Alpha-Synuclein for Neurodegenerative Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASD-004 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AV-1947D - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AV-1948D - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AV-1949D - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AV-1950D - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AV-1950R - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BAN-0805 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BIIB-054 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CLR-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DPC-003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ENT-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LuAF-82422 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MEDI-1341 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit Alpha Synuclein for Parkinson's Disease and Lewy Body Dementia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit Tau, Amyloid Beta and Alpha-Synuclein for Neurodegenerative Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit Alpha Synuclein for Central Nervous System Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NLFPD-1233 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NPT-088 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NPT-10018A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NPT-189 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NPT-20011 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PD-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PD-03 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PD-04 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Posiphen - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PRX-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
quinpramine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Alpha-Synuclein for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Alpha-Synuclein for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Alpha-Synuclein and Lcn2 for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Alpha-Synuclein for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Inhibit Alpha Synuclein for Parkinson’s Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
trehalose - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
UB-312 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Dormant Products
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Product Development Milestones
Featured News & Press Releases
Jun 26, 2018: ProMIS Neurosciences Unique Discovery Platform Generates Potential New Antibody Therapeutics for Neurodegenerative Diseases
Jun 19, 2018: Prothena Announces Phase 1b Clinical Trial Results Of PRX002/RG7935 For Parkinson's Disease Published In JAMA Neurology
Jun 18, 2018: New immunotherapy could stop progression of Parkinson’s disease
May 14, 2018: AFFiRiS Announces Encouraging Long-term Data from a Series of First-in-Human Studies Using AFFITOPE PD01A Targeting Oligomeric Alpha-synuclein in Early Parkinson's Disease Patients
Mar 28, 2018: Proclara Biosciences Presents Preclinical Data Supporting the Development of GAIM-Based Therapies for Peripheral Amyloidoses at the 16th International Symposium on Amyloidosis
Mar 26, 2018: Enterin's Phase 2a RASMET Study in Patients With Parkinson's Disease Completes Enrollment
Mar 15, 2018: AC Immune prepares for a first in human study of a promising positron emission tomography tracer for Parkinson's disease
Mar 01, 2018: AFFiRiS Announces Results of a Phase I Clinical Study Using AFFITOPEs PD01A
Mar 01, 2018: AFFiRiS Announces Results of a Phase I Clinical Study Using AFFITOPEs PD03A
Dec 04, 2017: ICBII Announces the Filing of Orphan Drug Designation Application for the Use of alpha-Synuclein-SMART Molecule in the Treatment of Multiple System Atrophy
Nov 14, 2017: Proclara Biosciences Presents New Preclinical Data on GAIM-Based Therapy NPT088 at Society for Neuroscience Annual Meeting
Nov 14, 2017: Proclara Biosciences Presents New Preclinical Data on GAIM-Based Therapy NPT189 at Society for Neuroscience Annual Meeting
Oct 13, 2017: BioArctic's Patent for its Product Candidate Antibody BAN0805, for Parkinson's Disease, is Now Granted in Europe
Jul 18, 2017: Proclara Biosciences Presents New Preclinical Data Supporting the Development of NPT189 at Alzheimer’s Association International Conference (AAIC) 2017
Jul 17, 2017: Proclara Biosciences Announces Pipeline Progress
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Companies, H2 2018 (Contd.1)
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Products under Development by Companies, H2 2018 (Contd.2), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by AC Immune SA, H2 2018
Pipeline by AFFiRiS AG, H2 2018
Pipeline by BioArctic AB, H2 2018
Pipeline by Biogen Inc, H2 2018
Pipeline by Denali Therapeutics Inc, H2 2018
Pipeline by Fulcrum Therapeutics Inc, H2 2018
Pipeline by Genmab A/S, H2 2018
Pipeline by ICB International Inc, H2 2018
Pipeline by MedImmune LLC, H2 2018
Pipeline by Neuropore Therapies Inc, H2 2018
Pipeline by nLife Therapeutics SL, H2 2018
Pipeline by Priavoid GmbH, H2 2018
Pipeline by ProMIS Neurosciences Inc, H2 2018
Pipeline by Prothena Corp Plc, H2 2018
Pipeline by QR Pharma Inc, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd.1), H2 2018
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Companies, H2 2018 (Contd.1)
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Products under Development by Companies, H2 2018 (Contd.2), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by AC Immune SA, H2 2018
Pipeline by AFFiRiS AG, H2 2018
Pipeline by BioArctic AB, H2 2018
Pipeline by Biogen Inc, H2 2018
Pipeline by Denali Therapeutics Inc, H2 2018
Pipeline by Fulcrum Therapeutics Inc, H2 2018
Pipeline by Genmab A/S, H2 2018
Pipeline by ICB International Inc, H2 2018
Pipeline by MedImmune LLC, H2 2018
Pipeline by Neuropore Therapies Inc, H2 2018
Pipeline by nLife Therapeutics SL, H2 2018
Pipeline by Priavoid GmbH, H2 2018
Pipeline by ProMIS Neurosciences Inc, H2 2018
Pipeline by Prothena Corp Plc, H2 2018
Pipeline by QR Pharma Inc, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd.1), H2 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
COMPANIES MENTIONED
AC Immune SA
AFFiRiS AG
BioArctic AB
Biogen Inc
Denali Therapeutics Inc
Fulcrum Therapeutics Inc
Genmab A/S
ICB International Inc
MedImmune LLC
Neuropore Therapies Inc
nLife Therapeutics SL
Priavoid GmbH
ProMIS Neurosciences Inc
Prothena Corp Plc
QR Pharma Inc
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
COMPANIES MENTIONED
AC Immune SA
AFFiRiS AG
BioArctic AB
Biogen Inc
Denali Therapeutics Inc
Fulcrum Therapeutics Inc
Genmab A/S
ICB International Inc
MedImmune LLC
Neuropore Therapies Inc
nLife Therapeutics SL
Priavoid GmbH
ProMIS Neurosciences Inc
Prothena Corp Plc
QR Pharma Inc
